Abstract:The beta-amyloid hypothesis of Alzheimer's disease (AD) has resulted in current research focusing on lowering levels of brain beta-amyloid, a small peptide derived from amyloid precursor protein. Meanwhile, the signaling pathways downstream of beta-amyloid as well as beta-amyloid-independent mechanisms are also being vigorously pursued as potential disease-modifying targets. One such potential target is the protein kinase GCN2, which is important in controlling mRNA translation via phosphorylation of eukaryotic initiation factor 2α subunit (eIF2α). Interestingly, elevated eIF2α phosphorylation has been correlated with AD pathogenesis, potentially via mechanisms of oxidative stress. Here taking advantage of a mutant mouse model in which eIF2 a kinase GCN2 is deleted (GCN2 KO), we examined whether repression of eIF2α phosphorylation could alleviate synaptic and memory deficits associated with APP/PS1 AD model mice. Hippocampal long-term potentiation (LTP) was induced by high frequency-stimulation (HFS) at CA3-CA1 synapses. Spatial memory was estimated by doing Morris water maze. Immunofluorescence combined with confocal microscopy was used to detect dendritic co-localization. Western blot was used to examine regulation of protein levels. We found that phosphorylation of eIF2α was increased in human AD brains and in the hippocampus of APP/PS1 mutant mice, which are a model for AD. We also found that the increase in eIF2 a phosphorylation in the APP/PS1 mice was correlated with increases in the levels of GCN2 and ATF4 (activating transcription factor 4). Additionally, we found that GCN2 co-localized with phospho-eIF2α in dendritic processes of hippocampal neurons. In correlation, hippocampal LTP was intact in GCN2 KO mice treated with beta-amyloid 1–42 (500 nM), which caused LTP failure in wild type mice. Furthermore, we crossed APP/PS1 mouse with GCN2 KO mice and generated APP/PS1/GCN2 KO double mutant mice. We demonstrated that inhibition of eIF2α activity by deleting GCN2 prevented decline of spatial memory and synaptic function in APP/PS1 mouse (10–12 month old). Our findings indicate that AD-associated impairments in synaptic plasticity and memory can be prevented by decreasing GCN2-dependent eIF2 a phosphorylation, which might be linked to enhanced translation. These studies suggest that GCN2 and eIF2a are viable therapeutic targets for synaptic dysfunction in AD and other related dementia syndrome.

Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease.

Suppression of the kinase for elongation factor 2 alleviates mGluR-LTD impairments in a mouse model of Alzheimer’s disease

Suppression of the Kinase for Elongation Factor 2 Alleviates Mglur-Ltd Impairments in a Mouse Model of Alzheimer's Disease.

The eIF2α kinase PERK limits the expression of hippocampal metabotropic glutamate receptor-dependent long-term depression.

Suppression of Eif2α Kinases Alleviates Alzheimer's Disease–related Plasticity and Memory Deficits

Isoform-specific Effects of Neuronal Inhibition of AMPK Catalytic Subunit on LTD Impairments in a Mouse Model of Alzheimer’s Disease

Isoform-specific effects of neuronal inhibition of AMPK catalytic subunit on LTD impairments in a mouse model of Alzheimer's disease

Antagonists Targeting Eef2 Kinase Rescue Multiple Aspects of Pathophysiology in Alzheimer's Disease Model Mice

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Memory impairments in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A‐484954

O3–02–01: Reversal of Synaptic Plasticity and Spatial Memory Deficits in APP/PS1 Mice by Suppressing Protein Kinase GCN2

The MK2 cascade mediates transient alteration in mGluR‐LTD and spatial learning in a murine model of Alzheimer's disease

Homozygous knockout of eEF2K alleviates cognitive deficits in APP/PS1 Alzheimer's disease model mice independent of brain amyloid β pathology

Genetic Reduction of Eef2 Kinase Alleviates Pathophysiology in Alzheimer’s Disease Model Mice

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Β

P2‐157: BRAIN‐SPECIFIC REPRESSION OF AMPKα1 ALLEVIATES MEMORY DEFICITS AND SYNAPTIC FAILURE IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Genetic removal of eIF2α kinase PERK in mice enables hippocampal L-LTP independent of mTORC1 activity

Brain-specific repression of AMPK1 alleviates pathophysiology in Alzheimer's model mice

Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease.

Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.